Differential expression of osteocalcin during the metastatic progression of prostate cancer

Oncology Reports

Volumn 21, Issue 4, 2009, Pages 903-908

  Gardner, Thomas A ^a   Lee, Sang Jin ^b   Lee, Sang Don ^c   Li, Xiong ^a   Shirakawa, Toshihiro ^d   Kwon, Dong Deuk ^e,f   Park, Ra Young ^e,f   Ahn, Kyu Youn ^e,f   Jung, Chaeyong ^e,f  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b National Cancer Center   (South Korea)

^c Pusan National University School of Medicine   (South Korea)

^d KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e Chonnam National University Medical School   (South Korea)

^f Chonnam National University   (South Korea)

Author keywords

Metastasis; Osteocalcin; Prostate cancer

Indexed keywords

OSTEOCALCIN; RNA; MESSENGER RNA;

ARTICLE; BONE METASTASIS; CANCER GROWTH; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; BONE MARROW CANCER; DISEASE COURSE; GENETIC TRANSCRIPTION; GENETICS; METASTASIS; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; RNA SPLICING;

BONE MARROW NEOPLASMS; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; OSTEOCALCIN; PROSTATIC NEOPLASMS; RNA SPLICING; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 67449097420     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000302     Document Type: Article

References (36)

1. Celeste AJ, Rosen V, Buecker JL, Kriz R, Wang EA and Wozney JM: Isolation of the human gene for bone gla protein utilizing mouse and rat cDNA clones. EMBO J 5: 1885-1890, 1986.
2. Hauschka PV, Lian JB, Cole DE and Gundberg CM: Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev 69: 990-1047, 1989.
3. Thiede MA, Smock SL, Petersen DN, Grasser WA, Thompson DD and Nishimoto SK: Presence of messenger ribonucleic acid encoding osteocalcin, a marker of bone turnover, in bone marrow megakaryocytes and peripheral blood platelets. Endocrinology 135: 929-937, 1994.
4. Goltzman D: Mechanisms of the development of osteoblastic metastases. Cancer 80: 1581-1587, 1997.
5. Arai Y, Takeuchi H, Oishi K and Yoshida O: Osteocalcin: is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer? Prostate 20: 169-177, 1992.
6. Curatolo C, Ludovico GM, Correale M, et al: Advanced prostate cancer follow-up with prostate-specific antigen, prostatic acid phosphatase, osteocalcin and bone isoenzyme of alkaline phosphatase. Eur Urol 21 (Suppl. 1): 105-107, 1992.
7. Marcellini M, De Carli P, Abbolito MR, Mainiero G and Cantiani R: Serum osteocalcin in monitoring bone metastases in advanced prostatic cancer. Eur Urol 21 (Suppl. 1): 102-104, 1992.
8. Shih WJ, Wierzbinski B, Collins J, Magoun S, Chen IW and Ryo UY: Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements. J Nucl Med 31: 1486-1489, 1990.
9. Levedakou EN, Strohmeyer TG, Effert PJ and Liu ET: Expression of the matrix Gla protein in urogenital malignancies. Int J Cancer 52: 534-537, 1992.
10. Yeung F and Chung LW: Molecular basis of co-targeting prostate tumor and stroma. J Cell Biochem Suppl 38: 65-72, 2002.
11. Yeung F, Law WK, Yeh CH, et al: Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. J Biol Chem 277: 2468-2476, 2002.
12. Jung C, Ou YC, Yeung F, Frierson HF Jr and Kao C: Osteocalcin is incompletely spliced in non-osseous tissues. Gene 271: 143-150, 2001.
13. Herrington CS, Troncone G, Evans MF and McGee JO: Screening for high- and low-risk human papillomavirus types in single routine cervical smears by non-isotopic in situ hybridization. Cytopathology 3: 71-78, 1992.
14. Andersen H, Jensen ON, Moiseeva EP and Eriksen EF: A proteome study of secreted prostatic factors affecting osteoblastic activity: galectin-1 is involved in differentiation of human bone marrow stromal cells. J Bone Miner Res 18: 195-203, 2003.
15. Dai J, Kitagawa Y, Zhang J, et al: Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res 64: 994-999, 2004.
16. Koeneman KS, Yeung F and Chung LW: Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39: 246-261, 1999.
17. Kitagawa Y, Dai J, Zhang J, et al: Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. Cancer Res 65: 10921-10929, 2005.
18. Valta MP, Hentunen T, Qu Q, et al: Regulation of osteoblast differentiation: a novel function for FGF-8. Endocrinology, 2006.
19. Valta MP, Tuomela J, Bjartell A, Valve E, Vaananen HK and Harkonen P: FGF-8 is involved in bone metastasis of prostate cancer. Int J Cancer 123: 22-31, 2008.
20. Zayzafoon M, Abdulkadir SA and McDonald JM: Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines. J Biol Chem 279: 3662-3670, 2004.
21. Huang WC, Wu D, Xie Z, et al: Beta2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. Cancer Res 66: 9108-9116, 2006.
22. Nadiminty N, Lou W, Lee SO, et al: Prostate-specific antigen modulates genes involved in bone remodeling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2. Clin Cancer Res 12: 1420-1430, 2006.
23. Montecino M, Lian J, Stein G and Stein J: Changes in chromatin structure support constitutive and developmentally regulated transcription of the bone-specific osteocalcin gene in osteoblastic cells. Biochemistry 35: 5093-5102, 1996.
24. Frendo JL, Xiao G, Fuchs S, Franceschi RT, Karsenty G and Ducy P: Functional hierarchy between two OSE2 elements in the control of osteocalcin gene expression in vivo. J Biol Chem 273: 30509-30516, 1998.
25. Hassan MQ, Javed A, Morasso MI, et al: Dlx3 transcriptional regulation of osteoblast differentiation: temporal recruitment of Msx2, Dlx3, and Dlx5 homeodomain proteins to chromatin of the osteocalcin gene. Mol Cell Biol 24: 9248-9261, 2004.
26. Javed A, Gutierrez S, Montecino M, et al: Multiple Cbfa/AML sites in the rat osteocalcin promoter are required for basal and vitamin D-responsive transcription and contribute to chromatin organization. Mol Cell Biol 19: 7491-7500, 1999.
27. Lian JB, Stein JL, Stein GS, et al: Contributions of nuclear architecture and chromatin to vitamin D-dependent transcriptional control of the rat osteocalcin gene. Steroids 66: 159-170, 2001.
28. Paredes R, Arriagada G, Cruzat F, et al: The Runx2 transcription factor plays a key role in the 1alpha,25-dihydroxy Vitamin D3-dependent upregulation of the rat osteocalcin (OC) gene expression in osteoblastic cells. J Steroid Biochem Mol Biol 89-90: 269-271, 2004.
29. Javed A, Guo B, Hiebert S, et al: Groucho/TLE/R-esp proteins associate with the nuclear matrix and repress RUNX (CBF (alpha)/AML/ PEBP2(alpha)) dependent activation of tissue-specific gene transcription. J Cell Science 113 (Pt 12): 2221-2231, 2000.
30. Sierra J, Villagra A, Paredes R, et al: Regulation of the bonespecific osteocalcin gene by p300 requires Runx2/Cbfa1 and the vitamin D3 receptor but not p300 intrinsic histone acetyltransferase activity. Mol Cell Biol 23: 3339-3351, 2003.
31. Villagra A, Cruzat F, Carvallo L, et al: Chromatin remodeling and transcriptional activity of the bone-specific osteocalcin gene require CCAAT/enhancer-binding protein beta-dependent recruitment of SWI/SNF activity. J Biol Chem 281: 22695-22706, 2006.
32. Koeneman KS, Kao C, Ko SC, et al: Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J Urol 18: 102-110, 2000.
33. Kubo H, Gardner TA, Wada Y, et al: Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoterdriven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther 14: 227-241, 2003.
34. Matsubara S, Wada Y, Gardner TA, et al: A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res 61: 6012-6019, 2001.
35. McCarthy HO, Coulter JA, Worthington J, Robson T and Hirst DG: Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer. J Gene Med 9: 511-520, 2007.
36. Shirakawa T, Terao S, Hinata N, et al: Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer. Hum Gene Ther 18: 1225-1232, 2007.